Logo
x

Search

Subscribe Now

Supply Agreement

Merck Signs a Supply Agreement with Werewolf for WTX-124 INDUKINE Program to Treat Solid Tumors

Merck Signs a Supply Agreement with Werewolf for WTX-124 INDUKINE Program to Treat Solid Tumors

  • August 19, 2021
BeiGene Signs a Supply Agreement with PureTech for LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid Tumors

BeiGene Signs a Supply Agreement with PureTech for LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid Tumors

  • July 8, 2021
Merck Collaborates with OncoSec to Evaluate TAVO (tavokinogene telseplasmid) + Keytruda (pembrolizumab) in P-III KEYNOTE-C87 Trial for Late-Stage Metastatic Melanoma

Merck Collaborates with OncoSec to Evaluate TAVO (tavokinogene telseplasmid) + Keytruda (pembrolizumab) in P-III KEYNOTE-C87 Trial...

  • July 7, 2021
Merck Signs ~$1.2B Supply Agreement with US Government for Molnupiravir to Treat COVID-19

Merck Signs ~$1.2B Supply Agreement with US Government for Molnupiravir to Treat COVID-19

  • June 10, 2021
Prestige Biopharma and Pharmapark Sign an Exclusive License and Supply Agreement to Commercialize HD204 (biosimilar- bevacizumab) in Russia

Prestige Biopharma and Pharmapark Sign an Exclusive License and Supply Agreement to Commercialize HD204 (biosimilar- bevacizumab)...

  • April 16, 2021
PhaseBio Signs a Supply Agreement with BioVectra to Support the Development and Commercialization of Bentracimab

PhaseBio Signs a Supply Agreement with BioVectra to Support the Development and Commercialization of Bentracimab

  • March 12, 2021
Merck Signs ~$1.2B Supply Agreement with US Government for Molnupiravir to Treat COVID-19

    Merck Signs ~$1.2B Supply Agreement with US Government for Molnupiravir to Treat COVID-19

    • June 10, 2021
    Prestige Biopharma and Pharmapark Sign an Exclusive License and Supply Agreement to Commercialize HD204 (biosimilar- bevacizumab) in Russia

      Prestige Biopharma and Pharmapark Sign an Exclusive License and Supply Agreement to Commercialize HD204 (biosimilar- bevacizumab)...

      • April 16, 2021
      PhaseBio Signs a Supply Agreement with BioVectra to Support the Development and Commercialization of Bentracimab

        PhaseBio Signs a Supply Agreement with BioVectra to Support the Development and Commercialization of Bentracimab

        • March 12, 2021
        AstraZenca Expands Supply Agreement with Cheplapharm for Atacand (candesartan cilexetil) and Atacand Plus (candesartan cilexetil + hydrochlorothiazide) to Cheplapharm

          AstraZenca Expands Supply Agreement with Cheplapharm for Atacand (candesartan cilexetil) and Atacand Plus (candesartan cilexetil +...

          • October 30, 2020
          AstraZeneca Expands Supply Agreement with Oxford Biomedica for AZD1222 to Combat COVID-19

            AstraZeneca Expands Supply Agreement with Oxford Biomedica for AZD1222 to Combat COVID-19

            • September 1, 2020
            Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant to Manufacture and Supply AXO-Lenti-PD for Parkinson

              Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant to Manufacture and Supply AXO-Lenti-PD for Parkinson's Di...

              • July 31, 2020
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.